Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations

Medicine, Pharmacology, Pharmacotherapy +14

Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999

Statement on sarcoidosis · American Journal of Respiratory and Critical Care Medicine · 1999 · 2K citations

Medicine, Internal Medicine, Pulmonary Function Testing +6

A Standardized Breath Holding Technique for the Clinical Measurement of the Diffusing Capacity of the Lung for Carbon Monoxide 1

C M Ogilvie, Robert Förster, William S. Blakemore et al. · Journal of Clinical Investigation · 1957 · 1.2K citations · Full text

Health Professions, Clinical Sciences, Internal Medicine +14

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

E P Sampaio, Euzenir Nunes Sarno, Ruth Galilly et al. · The Journal of Experimental Medicine · 1991 · 1.2K citations · Full text

Medicine, Immunology, Pharmacology +14

The Effects of Body Mass Index on Lung Volumes

Richard L. Jones, Mary-Magdalene U. Nzekwu · CHEST Journal · 2006 · 1.1K citations

Health Professions, Anatomy, Physiology +13